Teva Pharmaceutical Industries Current Ratio 2006-2018 | TEVA

Current and historical current ratio for Teva Pharmaceutical Industries (TEVA) from 2006 to 2018. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations. Teva Pharmaceutical Industries current ratio for the three months ending September 30, 2018 was 0.94.
Teva Pharmaceutical Industries Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2018-09-30 $13.88B $14.83B 0.94
2018-06-30 $14.71B $14.22B 1.04
2018-03-31 $14.69B $14.76B 1.00
2017-12-31 $15.38B $17.92B 0.86
2017-09-30 $16.23B $16.94B 0.96
2017-06-30 $14.60B $15.46B 0.94
2017-03-31 $14.84B $15.90B 0.93
2016-12-31 $17.23B $18.49B 0.93
2016-09-30 $17.39B $19.29B 0.90
2016-06-30 $18.34B $14.41B 1.27
2016-03-31 $16.99B $12.91B 1.32
2015-12-31 $18.40B $13.01B 1.42
2015-09-30 $12.50B $12.98B 0.96
2015-06-30 $13.30B $14.47B 0.92
2015-03-31 $15.71B $12.47B 1.26
2014-12-31 $14.40B $12.29B 1.17
2014-09-30 $13.92B $11.67B 1.19
2014-06-30 $13.55B $11.85B 1.14
2014-03-31 $13.45B $11.40B 1.18
2013-12-31 $13.72B $11.97B 1.15
2013-09-30 $13.91B $12.16B 1.14
2013-06-30 $14.09B $12.84B 1.10
2013-03-31 $14.42B $12.36B 1.17
2012-12-31 $16.36B $12.89B 1.27
2012-09-30 $14.98B $10.63B 1.41
2012-06-30 $14.23B $10.01B 1.42
2012-03-31 $14.97B $13.63B 1.10
2011-12-31 $14.45B $13.68B 1.06
2011-09-30 $13.02B $11.48B 1.13
2011-06-30 $12.60B $10.05B 1.25
2011-03-31 $12.05B $8.89B 1.36
2010-12-31 $12.04B $9.69B 1.24
2010-09-30 $11.86B $9.32B 1.27
2010-06-30 $14.44B $8.18B 1.77
2010-03-31 $12.61B $8.34B 1.51
2009-12-31 $12.14B $7.60B 1.60
2009-09-30 $11.46B $7.23B 1.58
2009-06-30 $11.04B $7.24B 1.52
2009-03-31 $11.14B $8.57B 1.30
2008-12-31 $11.43B $8.48B 1.35
2008-09-30 $10.95B $4.98B 2.20
2008-06-30 $10.82B $5.46B 1.98
2008-03-31 $10.49B $5.75B 1.82
2007-12-31 $9.86B $5.37B 1.84
2007-09-30 $9.13B $5.22B 1.75
2007-06-30 $8.67B $4.74B 1.83
2007-03-31 $8.02B $4.64B 1.73
2006-12-31 $7.64B $4.07B 1.88
2006-09-30 $7.24B $3.94B 1.84
2006-06-30 $6.67B $3.99B 1.67
2006-03-31 $5.86B $3.68B 1.59
2005-12-31 $5.51B $2.26B 2.44
2005-09-30 $4.40B $2.17B 2.03
2005-06-30 $4.26B $2.09B 2.04
2005-03-31 $4.25B $2.19B 1.94
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $22.626B $22.385B
TEVA Pharmaceuticals USA, the business is to develop, manufacture, and market generic pharmaceuticals. Teva USA sells its products to chains, wholesalers, distributors, hospitals, managed care entities, and government agencies. The company markets a variety of dosage forms, including both extended and immediate release tablets and capsules, creams, ointments, solutions, and suspensions. Key therapeutic areas are the analgesic, anti-infective, cardiovascular, CNS, dermatological and anti-inflammatory categories.
Stock Name Country Market Cap PE Ratio
Allergan (AGN) Ireland $53.085B 9.11
Mylan (MYL) United Kingdom $18.006B 7.41
Bausch Health Cos (BHC) Canada $8.859B 6.41
Dr Reddy's Laboratories (RDY) India $5.791B 23.13
Mallinckrodt Public Limited Company (MNK) United Kingdom $2.571B 4.29
Supernus Pharmaceuticals (SUPN) United States $2.296B 21.75
Amphastar Pharmaceuticals (AMPH) United States $0.953B 103.35
Akorn (AKRX) United States $0.860B 0.00
Homology Medicines (FIXX) United States $0.769B 0.00
Assembly Biosciences (ASMB) United States $0.628B 0.00
CymaBay Therapeutics (CBAY) United States $0.574B 0.00
Corium (CORI) United States $0.459B 0.00
Progenics Pharmaceuticals (PGNX) United States $0.455B 0.00
Voyager Therapeutics (VYGR) United States $0.405B 0.00
Adamas Pharmaceuticals (ADMS) United States $0.296B 0.00
Teligent (TLGT) United States $0.137B 0.00
Sol-Gel Technologies (SLGL) Israel $0.132B 0.00
Zynerba Pharmaceuticals (ZYNE) United States $0.093B 0.00
Aevi Genomic Medicine (GNMX) United States $0.071B 0.00
Acasti Pharma (ACST) Canada $0.057B 0.00
Aquinox Pharmaceuticals (AQXP) Canada $0.051B 0.00
Evoke Pharma (EVOK) United States $0.042B 0.00
Agile Therapeutics (AGRX) United States $0.029B 0.00
Pernix Therapeutics Holdings (PTX) United States $0.008B 0.00